• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在 MELD 系统下,哪种治疗方案更具成本效益:原发性肝移植,还是米兰标准范围内肝癌切除术后或局部区域治疗后的挽救性移植?

Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria?

机构信息

Department of Surgery, Vanderbilt Transplant Center, Vanderbilt University Medical Center, Nashville, TN, USA.

出版信息

HPB (Oxford). 2011 Nov;13(11):783-91. doi: 10.1111/j.1477-2574.2011.00355.x. Epub 2011 Aug 19.

DOI:10.1111/j.1477-2574.2011.00355.x
PMID:21999591
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3238012/
Abstract

OBJECTIVE

The optimal strategy for treating hepatocellular carcinoma (HCC), a disease with increasing incidence, in patients with Child-Pugh class A cirrhosis has long been debated. This study evaluated the cost-effectiveness of hepatic resection (HR) or locoregional therapy (LRT) followed by salvage orthotopic liver transplantation (SOLT) vs. that of primary orthotopic liver transplantation (POLT) for HCC within the Milan Criteria.

METHODS

A Markov-based decision analytic model simulated outcomes, expressed in costs and quality-adjusted life years (QALYs), for the three treatment strategies. Baseline parameters were determined from a literature review. Sensitivity analyses tested model strength and parameter variability.

RESULTS

Both HR and LRT followed by SOLT were associated with earlier recurrence, decreased survival, increased costs and decreased quality of life (QoL), whereas POLT resulted in decreased recurrence, increased survival, decreased costs and increased QoL. Specifically, HR/SOLT yielded 3.1 QALYs (at US$96 000/QALY) and LRT/SOLT yielded 3.9 QALYs (at US$74 000/QALY), whereas POLT yielded 5.5 QALYs (at US$52 000/QALY). Sensitivity analyses supported these findings at clinically meaningful probabilities.

CONCLUSIONS

Under the Model for End-stage Liver Disease (MELD) system, in patients with HCC within the Milan Criteria, POLT increases survival and QoL at decreased costs compared with HR or LRT followed by SOLT. Therefore, POLT is the most cost-effective strategy for the treatment of HCC.

摘要

目的

对于伴有发病率不断增加的肝硬化 A 级患者,如何治疗肝细胞癌(HCC)一直存在争议。本研究评估了米兰标准内 HCC 患者行肝切除术(HR)或局部区域治疗(LRT)联合挽救性原位肝移植(SOLT)与直接行原位肝移植(POLT)的成本效益。

方法

采用马尔可夫决策分析模型模拟三种治疗策略的结局,以成本和质量调整生命年(QALY)表示。基线参数来自文献复习。敏感性分析测试了模型的强度和参数的变异性。

结果

HR 和 LRT 联合 SOLT 均与更早的复发、更低的生存率、更高的成本和更低的生活质量(QoL)相关,而 POLT 则与更低的复发、更高的生存率、更低的成本和更高的 QoL 相关。具体而言,HR/SOLT 产生 3.1 个 QALY(成本为 96000 美元/QALY),LRT/SOLT 产生 3.9 个 QALY(成本为 74000 美元/QALY),而 POLT 产生 5.5 个 QALY(成本为 52000 美元/QALY)。在具有临床意义的概率下,敏感性分析支持这些发现。

结论

在终末期肝病模型(MELD)系统下,对于米兰标准内的 HCC 患者,与 HR 或 LRT 联合 SOLT 相比,POLT 以较低的成本提高了生存率和 QoL,因此是治疗 HCC 的最具成本效益的策略。

相似文献

1
Which is more cost-effective under the MELD system: primary liver transplantation, or salvage transplantation after hepatic resection or after loco-regional therapy for hepatocellular carcinoma within Milan criteria?在 MELD 系统下,哪种治疗方案更具成本效益:原发性肝移植,还是米兰标准范围内肝癌切除术后或局部区域治疗后的挽救性移植?
HPB (Oxford). 2011 Nov;13(11):783-91. doi: 10.1111/j.1477-2574.2011.00355.x. Epub 2011 Aug 19.
2
Effectiveness of locoregional therapy before living donor liver transplantation in patients with hepatocellular carcinoma who meet the Milan criteria.符合米兰标准的肝细胞癌患者在活体肝移植前进行局部区域治疗的有效性。
Transplant Proc. 2012 Mar;44(2):403-8. doi: 10.1016/j.transproceed.2012.01.067.
3
The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma.肝切除术、消融术和肝移植治疗早期肝细胞癌的相对净健康效益。
World J Surg. 2015 Jun;39(6):1474-84. doi: 10.1007/s00268-015-2987-7.
4
Cost-effectiveness of hepatic resection versus percutaneous radiofrequency ablation for early hepatocellular carcinoma.肝切除术与经皮射频消融治疗早期肝细胞癌的成本效益比较。
J Hepatol. 2013 Aug;59(2):300-7. doi: 10.1016/j.jhep.2013.04.009. Epub 2013 Apr 18.
5
Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria.米兰标准范围内早期肝细胞癌肝切除与肝移植的成本效益分析。
Hepatology. 2015 Jan;61(1):227-37. doi: 10.1002/hep.27135. Epub 2014 May 29.
6
Cost-effectiveness of Stereotactic Body Radiation Therapy versus Radiofrequency Ablation for Hepatocellular Carcinoma: A Markov Modeling Study.立体定向体部放射治疗与射频消融治疗肝细胞癌的成本效益:一项马尔可夫模型研究
Radiology. 2017 May;283(2):460-468. doi: 10.1148/radiol.2016161509. Epub 2017 Jan 3.
7
Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor.基于效用的肝细胞癌患者肝移植选择标准:一项使用甲胎蛋白模型作为生存预测指标的多中心队列研究
Liver Transpl. 2015 Oct;21(10):1250-8. doi: 10.1002/lt.24214.
8
Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States.肝细胞癌的早期检测和治疗:法国和美国的成本效益分析。
Hepatology. 2017 Apr;65(4):1237-1248. doi: 10.1002/hep.28961. Epub 2017 Feb 8.
9
Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation?复发性肝细胞癌的治疗策略:挽救性移植、再次切除还是射频消融?
Liver Transpl. 2013 Apr;19(4):411-9. doi: 10.1002/lt.23605. Epub 2013 Mar 17.
10
Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma.小肝癌治疗策略的生存与成本效益分析。
Liver Transpl. 2010 Oct;16(10):1186-94. doi: 10.1002/lt.22129.

引用本文的文献

1
Hepatocellular Carcinoma cells: activity of Amygdalin and Sorafenib in Targeting AMPK /mTOR and BCL-2 for anti-angiogenesis and apoptosis cell death.肝癌细胞:杏仁苷和索拉非尼在靶向 AMPK/mTOR 和 BCL-2 以抑制血管生成和诱导细胞凋亡中的活性。
BMC Complement Med Ther. 2023 Sep 19;23(1):329. doi: 10.1186/s12906-023-04142-1.
2
Optimal treatment for small HCC (<3 cm): Resection, liver transplantation, or locoregional therapy?小肝癌(<3厘米)的最佳治疗方法:手术切除、肝移植还是局部区域治疗?
JHEP Rep. 2023 Apr 25;5(8):100781. doi: 10.1016/j.jhepr.2023.100781. eCollection 2023 Aug.
3
A Systematic Review of Cost-Effectiveness Analyses for Hepatocellular Carcinoma Treatment.肝细胞癌治疗成本效益分析的系统评价
Pharmacoecon Open. 2022 Jan;6(1):9-19. doi: 10.1007/s41669-021-00298-z. Epub 2021 Aug 24.
4
Clinical Management of Liver Cancer in India and Other Developing Nations: A Focus on Radiation Based Strategies.印度及其他发展中国家肝癌的临床管理:聚焦基于放射治疗的策略
Oncol Ther. 2021 Dec;9(2):273-295. doi: 10.1007/s40487-021-00154-4. Epub 2021 May 27.
5
Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians.肝细胞癌监测与治疗的经济学意义:临床医生指南。
Pharmacoeconomics. 2020 Jan;38(1):5-24. doi: 10.1007/s40273-019-00839-9.
6
Liver Resection and Surgical Strategies for Management of Primary Liver Cancer.原发性肝癌的肝切除及手术治疗策略
Cancer Control. 2018 Jan-Mar;25(1):1073274817744621. doi: 10.1177/1073274817744621.
7
The Warsaw Proposal for the Use of Extended Selection Criteria in Liver Transplantation for Hepatocellular Cancer.《华沙肝细胞癌肝移植扩展选择标准应用提案》
Ann Surg Oncol. 2017 Feb;24(2):526-534. doi: 10.1245/s10434-016-5500-0. Epub 2016 Aug 16.
8
Resection for hepatocellular carcinoma.肝细胞癌切除术
J Clin Exp Hepatol. 2014 Aug;4(Suppl 3):S90-6. doi: 10.1016/j.jceh.2014.07.002. Epub 2014 Aug 27.
9
The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations.印度肝脏研究国家协会(INASL)关于印度肝细胞癌预防、诊断和管理的共识:普里建议
J Clin Exp Hepatol. 2014 Aug;4(Suppl 3):S3-S26. doi: 10.1016/j.jceh.2014.04.003. Epub 2014 May 22.
10
The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma.肝切除术、消融术和肝移植治疗早期肝细胞癌的相对净健康效益。
World J Surg. 2015 Jun;39(6):1474-84. doi: 10.1007/s00268-015-2987-7.

本文引用的文献

1
Global cancer statistics.全球癌症统计数据。
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4.
2
Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation.射频消融治疗肝细胞癌作为肝移植的桥梁。
HPB (Oxford). 2011 Jan;13(1):24-32. doi: 10.1111/j.1477-2574.2010.00228.x. Epub 2010 Nov 8.
3
Survival and cost-effectiveness analysis of competing strategies in the management of small hepatocellular carcinoma.小肝癌治疗策略的生存与成本效益分析。
Liver Transpl. 2010 Oct;16(10):1186-94. doi: 10.1002/lt.22129.
4
Molecular signature of early hepatocellular carcinoma.早期肝细胞癌的分子特征。
Oncology. 2010 Jul;78 Suppl 1:36-9. doi: 10.1159/000315228. Epub 2010 Jul 8.
5
Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States.美国肝硬化患者中肝细胞癌监测的应用。
Hepatology. 2010 Jul;52(1):132-41. doi: 10.1002/hep.23615.
6
Gene expression in nontumoral liver tissue and recurrence-free survival in hepatitis C virus-positive hepatocellular carcinoma.非肿瘤性肝组织中的基因表达与丙型肝炎病毒阳性肝细胞癌的无复发生存。
Mol Cancer. 2010 Apr 9;9:74. doi: 10.1186/1476-4598-9-74.
7
Harm and benefits of primary liver resection and salvage transplantation for hepatocellular carcinoma.原发性肝癌切除术和挽救性移植的危害和益处。
Am J Transplant. 2010 Mar;10(3):619-27. doi: 10.1111/j.1600-6143.2009.02984.x. Epub 2010 Jan 29.
8
Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis.肝切除术与射频消融术治疗极早期肝细胞癌的比较:Markov 模型分析。
Hepatology. 2010 Apr;51(4):1284-90. doi: 10.1002/hep.23466.
9
Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma.肝移植与肝切除术治疗肝细胞癌。
J Surg Oncol. 2010 Jan 1;101(1):47-53. doi: 10.1002/jso.21415.
10
Hepatic resection versus radiofrequency ablation for hepatocellular carcinoma in cirrhotic individuals not candidates for liver transplantation: a Markov model decision analysis.肝切除与射频消融治疗不适合肝移植的肝硬化肝细胞癌患者:马尔可夫模型决策分析
Am J Surg. 2009 Sep;198(3):396-406. doi: 10.1016/j.amjsurg.2009.01.016. Epub 2009 Jun 11.